The myocardium consists of numerous cell types embedded in organized layers of ECM (extracellular matrix) and requires an intricate network of blood and lymphatic vessels and nerves to provide nutrients and electrical coupling to the cells. Although much of the focus has been on cardiomyocytes, these cells make up <40% of cells within a healthy adult heart. Therefore, repairing or regenerating cardiac tissue by merely reconstituting cardiomyocytes is a simplistic and ineffective approach. In fact, when an injury occurs, cardiac tissue organization is disrupted at the level of the cells, the tissue architecture, and the coordinated interaction among the cells. Thus, reconstitution of a functional tissue must reestablish electrical and mechanical communication between cardiomyocytes and restore their surrounding environment. It is also essential to restore distinctive myocardial features, such as vascular patency and pump function. In this article, we review the current status, challenges, and future priorities in cardiac regenerative or reparative medicine. In the first part, we provide an overview of our current understanding of heart repair and comment on the main contributors and mechanisms involved in innate regeneration. A brief section is dedicated to the novel concept of rejuvenation or regeneration, which we think may impact future development in the field. The last section describes regenerative therapies, where the most advanced and disruptive strategies used for myocardial repair are discussed. Our recommendations for priority areas in studies of cardiac regeneration or repair are summarized in Tables 1 and 2 
C ardiovascular regenerative and reparative medicine (herein referred to simply as regenerative) began about 2 decades ago with the premise that transplanted cells would proliferate, differentiate into functional cardiomyocytes, and reconstitute the function of damaged heart tissue. 1, 2 The excitement and promise were high, and cell therapy was viewed as a cure for cardiovascular disease. Within 2 years, several clinical trials were initiated. However, after 2 decades of research, cell therapy has not yet been proven to benefit patients with cardiovascular disease. The results have been mixed. Studies of ST-segment-elevation myocardial infarction have been disappointing, 3 whereas those of refractory angina consistently indicate beneficial effects. 4 Studies of chronic heart failure have been encouraging, although conclusive demonstration of therapeutic efficacy in this setting is still lacking. 3, [5] [6] [7] This has led us to posit that global changes are needed to achieve progress in the field of cardiovascular regenerative medicine. We started creating cooperative multidisciplinary networks, unifying our efforts and knowledge, and coordinating future research. 5 Most importantly, a deeper understanding of the fundamental processes that govern the complex phenomenon of regeneration is essential to guide the future development of this field. In this essay, we provide a comprehensive analysis of the complex array of factors involved in cardiac regeneration and repair, and we discuss the main challenges and priority areas for future studies, which are summarized in Tables 1 and 2. in appropriate ratios, forming a cardiac architecture and coordinating cell-cell connections similar to those observed in native cardiac tissue ( Figure 1 ). Orchestrated division, differentiation and dedifferentiation, migration, integration, infiltration, and maturation of cardiomyocytes and noncardiomyocytes within a scaffold are likely required to form newly functional tissue. Moreover, although regeneration/repair shares many common pathways with organogenesis during embryonic development, 10 it involves additional complexities such as injury-related inflammation and the need to remove damaged/necrotic cells.
Despite its complexity, there is evidence that cardiac regeneration occurs in some species. Most of the knowledge on spontaneous cardiac regeneration comes from lower vertebrates, such as teleost fish (zebrafish) and urodeles (newts and salamanders), since they preserve this regenerative capability through their entire life cycle. [11] [12] [13] More evolved organisms lose the ability to self-regenerate, although the reasons are still uncertain. In mammals, a robust regenerative capacity exists in the neonatal period in mice, including after ischemic injury, ventricular resection, and cryoinjury. 14, 15 Telomere dysfunction and telomerase inactivation soon after birth are some of the hypotheses proposed to explain the loss of regenerative ability after the neonatal period in mice. 16 In humans, the existence of cardiac regeneration is still debated. Cases of complete functional recovery and apparent regeneration have been reported in a newborn child with myocardial infarction and in infants after cardiac surgery. 17, 18 Magnetic resonance imaging evidence of decreased delayed gadolinium enhancement and increased viable tissue, which is suggestive but not conclusive evidence of myocardial regeneration, 19 has been provided by several cell therapy clinical trials. 6 These findings suggest the possibility of reactivating or upregulating regeneration-related pathways that are silenced or downregulated at some stage after birth in the human heart. Verifying the existence of cardiac regeneration in humans and unraveling its underlying pathways and control mechanisms are a priority for regenerative medicine research.
Components of Myocardial Regeneration
As mentioned above, regeneration involves reconstitution of multiple cell types and structures within the heart after an injury. The main challenge is to restore the pool of lost cardiomyocytes, although reconstitution of other cells and scaffold architecture is likewise important.
Sources of New Cardiomyocytes
Several potential sources of nascent cardiomyocytes exist. They can either be provided by exogenous cells or, theoretically, derived internally from stem or progenitor cells. Exogenous or extrinsic replacement generally refers to implantation of cardiomyocytes differentiated in vitro from embryonic stem cells or induced pluripotent stem cells (iPSCs). Generation of cardiomyocytes from exogenous cells has been extensively discussed in previous reviews 20, 21 and is beyond the scope of this article. Endogenous repair occurs when cardiomyocytes are generated directly within the heart and it is one of the innate mechanisms of regeneration. New cardiomyocytes can potentially arise from cardiomyocytes or putative cardiac stem cells, among others. [22] [23] [24] [25] [26] Daughter cardiomyocytes, originating by simple division (mitosis) of a parental cell, can also potentially dedifferentiate into a more primitive cell type, proliferate, and then differentiate back into new cardiomyocytes. Finally, differentiation of heart resident stem/progenitor cells into new cardiomyocytes has been postulated to be a mechanism of regeneration, although infrequent. Fate mapping studies in zebrafish and mice have demonstrated that, both after injury and during normal heart homeostasis, almost all new cardiomyocytes arise from the preexisting pool of cardiomyocytes. 25, 27, 28 This suggests that resident cardiomyocytes are capable of reentering the cell cycle and dividing under certain circumstances. In most species, cardiomyocytes exit the cell cycle after birth, but in humans, ≈25% of them undergo a further cycle of nuclear division without cytokinesis resulting in binucleation. 29 Increasing evidence, however, suggests that cardiomyocytes do renew even during adulthood, although their proliferation occurs at a very low rate and decreases progressively from 1% per year in a 25-years-old adult to 0.45% at age 75. 30 Why the cell cycle is downregulated and more importantly, how to induce cardiomyocytes to reenter the cell cycle are essential questions that need to be answered. A recent study, using fate mapping of hypoxic cells, identified a rare population of HIF-1α (hypoxia-inducible factor 1α) positive cardiomyocytes that importantly contributed to new cardiomyocyte formation in the adult heart. 31 Other factors associated with cell cycle regulation in cardiomyocytes are p38 MAPK (mitogen-activated protein kinase) and MEIS1 (myeloid ecotropic viral integration site 1 homolog), 32, 33 both related to the inhibition of cell proliferation. NRG1 (Neuregulin 1) is an emerging ligand, agonist of ERBB2 ( epidermal growth factor receptor) and ERBB4 receptor tyrosine kinases of the epidermal growth factor receptor family, that induces proliferation of adult cardiomyocytes in vitro and in vivo. 34 Interestingly, NRG1 seems to stimulate proliferation independent of the ploidy of the cell (polyploidization, or presence of >2 sets of chromosomes within the cell, is thought to suppress further cell cycle entry).
Frequently the efficacy of regenerative approaches is measured by their ability to induce cardiomyocytes proliferation. Therefore, correct evaluation of proliferation is essential and should be differentiated from cell cycle activity, which is the one reflected by the typical readouts of BrdU (bromodeoxyuridine/5-bromo-2'-deoxyuridine), Ki67 expression, and Aurora B. 35 In fact, the distinction between true cardiomyocyte renewal and polyploidization is one of the central questions discussed in the consensus statement on cardiomyocyte regeneration. 36 Finally, whether regenerative therapy-induced cardiomyocyte proliferation is just an epiphenomenon or is responsible for the observed improvement of cardiac function still has to be clarified. In part, this will depend on the number of new cardiomyocytes formed, which must be carefully quantified and reported in experimental studies; simply showing examples of new myocytes is not adequate. In addition, many more questions need to be addressed (Table 1) .
Crucial Role of Inflammatory and Immune Cells in Heart Regeneration
Contrary to classical belief, inflammation is not necessarily an impediment to tissue regeneration. In fact, monocytes and macrophages are required for cardiac regeneration, 37 and injury-induced cardiomyocyte proliferation is inhibited by immunosuppression. 38 Similarly, blockade of IL (interleukin)-6 and its downstream effector, STAT (signal transducer and activator of transcription) 3, suppresses cardiac regeneration after apical resection in neonatal hearts. 38 A recent study analyzed the transcriptional signature after apical resection in 3 model organisms (zebrafish, axolotl, and neonatal mice) and concluded that activation of C5aR1 (activated by complement components of the innate immune system) To what extent does cardiac rejuvenation affect regenerative mechanisms and cardioprotection?
A deeper understanding of human developmental processes is needed to unravel regenerative biology. Use of organoids, tiny 3-dimensional cellular structures resembling the organs, to provide more dynamic and physiological models on a dish, will help to understand development and regeneration.
A clear differentiation of in vitro and in vivo proregenerative processes should be established to better define their clinical relevance.
Cardiac molecular imaging should be used for better noninvasive functional characterization of different cell types in health and during heart healing and as guidance for therapeutic interventions.
Cardiomyocytes
Can human mature cardiomyocytes proliferate and if so, what are the mechanisms that control this process?
Can one identify and track cardiomyocyte subpopulation/s that are capable of division in the adult heart based on ploidy and other characteristics?
Markers of cardiomyocyte proliferation (rather than cell cycle activity) should be identified.
What are the transcriptional pathways underlying cardiomyocyte dedifferentiation, replication, migration, and maturation?
What mechanisms direct cardiomyocytes division as opposed to polyploidization?
Inflammatory/immune cells
What differentiates proregenerative from scar/fibrosis-driving cell signaling?
By which mechanisms do the same signals drive divergent healing processes?
Deeper characterization is needed of the communication among immune cells, fibroblasts, endothelial cells, and cardiomyocytes.
Better understanding of macrophage functions will enable targeting of disease-promoting cellular functions and preservation of macrophage activities or subsets that are essential for defending homeostasis and proregenerative healing.
Fibroblasts
Proper definition and characterization of markers of fibroblasts in baseline and activated (myofibroblasts) states are needed.
The molecular circuitry that regulates fibroblasts activation needs to be elucidated to identify possible therapeutic approaches that might limit progressive cardiac fibrosis.
Are fibroblasts the only relevant source of collagen and extracellular matrix production in the heart, either at baseline or with acute and chronic injury?
Resident cardiac progenitors/epicardium Efforts should be made to harness the therapeutic effects of the epicardial response and clarify how it is modulated in the setting of regeneration vs scar formation.
The paracrine and progenitor cell components of the epicardial response should be defined and dissected.
Complete molecular and functional characterization of endogenous cardiac progenitors should be pursued.
Extracellular matrix
To what extent can components of extracellular matrix induce regeneration in vivo in an otherwise nonregenerative environment?
Can targeting extracellular matrix components be a sufficient therapeutic strategy for regeneration?
promotes cardiomyocyte proliferation. Activation of complement pathway components may, therefore, mediate successful cardiac regeneration. 39 Technological advances have permitted a better characterization of inflammatory/immune cells and macrophages/ monocytes including during cardiac repair. As a result, we know that resident macrophages in the heart are deployed there during embryonic development and they self-renew independently of blood monocytes. Surface expression of CCR2 (C-C chemokine receptor type 2), resulting in CCR2+ and CCR2-cells, varies regionally within the heart and participates in organ development. 40 CCR2-macrophages reside preferentially in the myocardial wall, are essential for neonatal cardiac regeneration, and actively participate in normal heart development, specifically in the formation of the coronary vasculature. In contrast, CCR2+ cells are in the endocardium and are dispensable for cardiogenesis. Moreover, they secrete chemoattractants and induce transendothelial leukocyte migration into an injured area during myocardial ischemia. CCR2-embryonic macrophages are replaced by CCR2+ blood monocyte-derived macrophages in adult hearts after injury. Evidence suggests that limiting CCR2+ influx may preserve embryonic CCR2-subsets and improve myocardial repair. 41 Macrophages have a central role in the crosstalk among cardiomyocytes, fibroblasts, endothelial cells, and ECM (extracellular matrix) components. 42 They may play a dual role after injury by secreting inflammatory cytokines, activating fibroblasts, remodeling the ECM, and ultimately driving the progression of heart failure. 43 However, they can be proregenerative by clearing necrotic debris and stimulating angiogenesis and cardiomyocyte proliferation. 44 Harnessing their proreparative mechanism(s) to promote heart regeneration versus their proinflammatory effect that exacerbates disease will require better understanding and regulation of different hematopoietic/immune cells involved in homeostasis and injury. 3 
The Enigmatic Fibroblasts
Fibroblasts are the cells that remodel injured myocardium providing structural integrity when other cells are lost. They are known for their primordial role in heart remodeling and Figure 1 . Different targets of the cardiac regenerative process. Although quantitative and qualitative restoration of cardiomyocytes has an important role in cardiac regeneration, other constitutive cardiac components are required to reach an optimal recovery of cardiac architecture and functionality after an injury. Pro-(green) and antiregenerative (red) factors influencing different heart components are shown. CCR2 indicates C-C chemokine receptor type 2; HIF-1α, hypoxia-inducible factor 1α; IL, interleukin; MAPK, mitogen-activated protein kinase; nAG, newt anterior gradient protein; SDF1, C-X-C motif chemokine 12; STAT3, signal transducer and activator of transcription 3; Tbx, T-box protein; and VEGF, vascular endothelial growth factor.
fibrosis after injury and their intimate structural and functional interconnection with cardiomyocytes. In a healthy human heart, it is estimated that roughly 50% of the cells are mesenchymal cells, which include fibroblasts and pericytes. 45 The majority of cardiac fibroblasts arise during embryonic development-80% of them are generated from the epicardium through epithelial-to-mesenchymal transition. 46 The concept of extracardiac cells (ie, hematopoietic cells) differentiating into cardiac fibroblasts has been ruled out. 47 These findings suggest that fibroblasts are formed in an organ-specific manner and may even be tailored to the function of the organ in which they are embedded.
In homeostatic conditions, fibroblasts are found in the adventitia and myocardial interstitium and are critical in maintaining the structural and mechanical properties of the heart. Recent studies indicate that tissue-resident fibroblasts differentiate into and constitute most of disease-activated fibroblasts and myofibroblasts after cardiac injury and in tissue fibrosis and remodeling. [46] [47] [48] Many facets of fibroblast biology remain a topic of ongoing debate, likely because of a lack of clear definition of cardiac fibroblasts. 49, 50 We now know that many functional characteristics attributed to cardiac fibroblasts in health and disease may be equivocal, as they relied on markers that were nonspecific or partially identified the pool of cardiac fibroblasts. Using newly generated and validated genetic lineagetracing mouse models, researchers can now more reliably address fundamental concepts in fibroblast biology; some of which are of extreme relevance for regenerative medicine ( Table 1) . As we unravel increasing evidence that adult fibroblasts share many cardiogenic transcription factors with endogenous cardiac progenitor cells (50), we can begin to address the critical question of whether cardiac progenitor cells and cardiac fibroblasts are the same cell type or arise from the same cells.
ECM: the Active Scenario Where Everything Happens
Although the ECM was initially considered an inert scaffold, we now understand that it is an organized and dynamic mesh of proteins, influencing cell proliferation, migration, intercellular signaling, and growth factor modulation. 51 The composition as well as the structure of the ECM influence the regenerative capability of the myocardium. Changes in physical conditions such as pressure overload may influence the architectural properties of the protein mesh. In fact, progressive stiffening and maturation of the ECM in a growing mouse were correlated with cardiomyocyte cell cycle arrest. 52 Similarly, in the failing human heart unloaded with a ventricular assist device, cell cycle reentry has been observed. 53 The ECM is a multicompartment structure that provides both microscopic and macroscopic cues for cell behavior. We propose that the balance between different ECM components differentiates regenerative ECM, where cells incorporate and function, from scarring ECM, where collagen fibers predominate. Fibronectin, heparin-binding epidermal growth factorlike growth factor, hyaluronic acid, tenascin C, periostin, and collagen are matricellular proteins. Many of the matricellular proteins stimulate cardiomyocyte proliferation in a paracrine fashion, 23, 54, 55 whereas collagen type I is thought to directly inhibit regeneration. 56 However, scar formation should not be considered necessarily a barrier to regeneration. Although not observed in mammals, in the zebrafish heart after cryoinjury, an extensive initial scar forms, which is replaced by cardiomyocytes over time. 57 The role of other nonprotein components of the ECM (extracellular vesicles [EVs] and noncoding RNAs) in regulation of the structure and function of the matrix is rapidly emerging. [58] [59] [60] Therapeutic targeting of these molecules may constitute an attractive approach to modulate heart remodeling and eventually, promote regeneration.
Many questions about ECM are still unanswered, as listed in Table 1 .
Neovascularization and Lymphangiogenesis
One of the most important prognostic factors in acute myocardial infarction is whether blood flow is restored by reopening the obstructed coronary artery. A continuous supply of nutrients, as well as routes for eliminating metabolic products, is essential for tissue health. Therefore, reestablishing blood perfusion is required to repair damaged myocardium. Furthermore, the vasculature is a critical component of any newly built myocardial tissue. In the absence of neovascularization following injury, the heart fails to repair and instead forms extensive fibrotic scar. 61 In fact, angiogenesis and arteriogenesis were recently identified as one of the hallmarks and phenomenon that precede cardiomyogenesis. 62 Although the precise mechanisms of neovascularization are not well defined, the epicardium has been proposed as a key player. After the injury, the epicardium is reactivated and secretes several classical angiogenic factors, including VEGF (vascular endothelial growth factor), CXCL12 or SDF1 (C-X-C motif chemokine 12), fibroblast growth factor, and retinoic acid. 63 These factors are thought to promote epithelial-to-mesenchymal transition of epicardium-derived cells that invade the underlying myocardium, giving rise to pericytes, smooth muscle cells, and fibroblasts. However, the origin of new endothelial cells is still unclear.
Our knowledge of the role of the lymphatic system in regeneration is limited. The lymphatic system actively participates in maintaining tissue fluid homeostasis and trafficking of immune cells. As mentioned earlier, inflammation can trigger activation of regenerative pathways. [37] [38] [39] It is also associated with profound lymphangiogenesis and lymphatic vessel remodeling. Removing the soaring numbers of inflammatory cells, excess cytokines, and cellular debris, and resolving the edema resulting from increased blood vascular permeability are of pivotal importance to facilitate tissue repair. 64 In rodents, induction of lymphangiogenesis with VEGF-C, the principal macrophage-derived cytokine mediator of lymphatic formation, improves healing, reduces fibrosis, and preserves myocardial function after myocardial infarction. 65 
Nervous System
Because innervation is required to maintain tissue trophy, denervated organs or body parts exhibit progressive atrophy and dysfunction. In recent decades, the role of nerves in regeneration has been demonstrated across different species and several nerve-derived cytokines (fibroblast growth factor, glial growth factor or glial-derived neurotrophic factor, nAG [newt anterior gradient protein]) implicated in the process have been described. [66] [67] [68] In recent studies, mechanical or chemical denervation of parasympathetic or sympathetic systems impaired cardiac regeneration in mice on injury. 69, 70 Conversely, spinal cord stimulation-induced sympathetic innervation of the infarcted heart was associated with improved heart remodeling and function. 71 It seems that a critical nerve density is a determining factor in cardiac regeneration and is an evolutionarily conserved pathway among different species.
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Rejuvenation for Regeneration
A decline in regenerative capacity, with subsequent loss of tissue homeostasis and function, is one of the features of aging organs. For instance, the lifelong regenerative capacity of muscle is gradually lost and is minimal in advanced age. 72 Emerging evidence indicates that the functional and numerical decline of satellite cells-the skeletal muscle adult stem cells-is a progressive process occurring throughout the lifetime of the organism. 73 At advanced old age, these cells become nonfunctional because of senescence and apoptosis. Tissues and organs with low baseline regenerative capacity, such as the heart, are the most vulnerable to the effect of chronological aging. In fact, aging is one of the most relevant risk factors for cardiovascular disease and poor prognosis. 74 At the cellular level, aged tissues are characterized by the presence of senescent cells which are thought to contribute to the progressive age-related organ dysfunction. 75 Senescent cells present extensive transcriptional changes, chronically stimulated DNA-damage response, specific senescence-associated secretome, and cell cycle arrest. 76 In the heart, virtually any cell type can turn senescent and manifest in a cell-specific manner. Because regeneration is an orchestrated process that involves different cell types, senescence may affect the global process of cardiac regeneration and repair in multiple ways. First, when affecting the cardiomyocytes, the progressively decreased age-related endogenous cardiomyogenesis caused by deactivation of proproliferative and activation of prosenescence pathways (as pointed out above) might be linked to the reduced cardiac regenerative ability after injury in aging individuals. 30 Moreover, senescent cardiomyocytes characterized by telomere shortening, DNA damage, and alterations in ploidy, 77, 78 present structural changes and functional decline, such as cell hypertrophy, abnormal contractility, and abnormal relaxation resulting in age-related diastolic dysfunction. In the case of resident cardiac progenitor cells, senescent cells lose the capacity to self-renew and their reparative (proliferation and differentiation) responses are blunted. Progenitor cell-dependent regeneration can be perturbed in a cell-autonomous manner (senescence affects directly the stem and progenitor cells) or by paracrine mechanisms (stem cell niche dysfunction caused by the senescence-associated secretome). 79 Finally, senescent interstitial cells, especially dysfunctional senescenceassociated secretome-secreting fibroblasts, 80 are essential in spreading the phenomenon of senescence through the whole heart with a direct effect on cells implicated in regeneration (ie, cardiomyocytes, stem, and progenitor cells). Moreover, senescence-associated secretome comprising proinflammatory cytokines, chemokines, and proteases 80, 81 contributes to ECM remodeling, progressive fibrosis, and increased myocardial stiffness in elderly individuals, while high collagen fibers deposition directly inhibits regeneration. 56 To counteract the deleterious effects of persistent cellular senescence, the antiaging or rejuvenating therapies target the promotion of cellular youthfulness. A range of interventions, from dietary to epigenetic modifiers, gene editing, and cellbased therapies, have been successfully tested in preclinical studies. 74 As confirmation of a close relationship between cellular rejuvenation and regeneration, 82 a variety of rejuvenating interventions have been shown to improve the regenerative ability and function of different organs, including the heart, [83] [84] [85] although the debate is still open. 86 So, while the concept remains to be confirmed, rejuvenation by genetic engineering, hypoxic preconditioning, drugs, growth factors, or exosomes may be plausible methods to enhance cardiac regeneration and repair by busting cardiomyocyte, cardiac progenitor cells and other nonparenchymal cell's viability and function. In conclusion, the notion that cellular rejuvenation, conceived as partial or total reversion of the features of senescence, bringing the cardiac phenotype to a younger state or, at least delaying its further age-related decline, is a new concept that will open new horizons in regenerative medicine research.
Regenerative Therapies
Multiple strategies have been used to induce cardiac regeneration in the past 2 decades. Classification of this broad spectrum of possible approaches in rigid groups is difficult because of their frequently overlapping mechanisms of action. From a conceptual standpoint, these therapies can be categorized as cell-based (ie, involving transplantation of stem/progenitor cells or cardiomyocytes cultured in vitro into the injured heart) and cell-free (ie, stimulators of endogenous repair, modified mRNAs, small-molecule chemical compounds, and recombinant proteins delivered with viral or nonviral DNA vectors or extracellular nanovesicles; Figure 2 ). Moreover, there is evidence that a multipronged approach, using a combination of different strategies in association with tissue engineering, may be required to achieve complete regeneration of the heart. 87 The concept of personalized or precision regenerative medicine is a consideration to be kept in mind when deciding on the treatment strategy. The specific disease phenotype, associated comorbidities and treatments, as well as the genetic background of each individual may be important to select which cell or cell-free product should be used to achieve the desired effect. In this section, we discuss some of the field's most prominent advances in recent years and those that might change the future of regenerative therapies. Comprehensive reviews on this topic have been published elsewhere.
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Gene Therapy and CRISPR/Cas9 Genome Editing
Gene therapy has been applied to many aspects of cardiovascular research 91 ; however, from a regenerative perspective applications of special interest include gene therapy to promote vasculogenesis in coronary artery disease, gene therapy targeting adverse myocardial remodeling, and endogenous cardiomyocyte proliferation 92 in heart failure. About the first one, a novel VEGF-D dNdC factor is being tested clinically in refractory angina by using percutaneous delivery of adenoviral vectors. 93 The novelty of VEGF-D dNdC is its lymphangiogenic potential, its angiogenic effects, and its stimulation of resident stem/progenitor cells in the treated muscles. 94 About adverse remodeling, a recent study has demonstrated that gene therapy targeting telomerase activation in the mouse heart protects from dilation and progressive dysfunction following myocardial infarction, with a concomitant reduction of the scar and increase in survival. 95 Elongated telomeres, proliferating cardiomyocytes, and a gene expression switch towards a regeneration signature of neonatal mice in adult animals were thought to underlie the observed functional improvements. This proofof-concept study indicated that the telomere-telomerase axis can be a conceptually novel, attractive, and promising target for cardiac regeneration and should be further examined in larger studies.
Over the years, promising preclinical gene therapy results have failed to find clinical translation. A low gene transfer and transduction efficiency of only 10% to 20% in the human heart might have contributed to these negative results. 91 Factors such as intrinsic characteristics of the vectors, delivery method, volume of injection, and matrix binding properties of the transgenes affect the final distribution and concentration of the therapeutic product. The use of adeno-associated virus with proven long-term efficacy in preclinical models is also limited in the clinical setting by the high prevalence of preexisting antibodies against many serotypes.
Transfer of nucleic acids with slowly degrading nanoparticles and exosomes has emerged as a potential therapeutic approach, and vectors with better cardiac tropism are being developed. Moreover, fast, efficient, and precise modern genome-editing technology has revolutionized the field of gene therapy in recent years. Among the currently used genomeediting tools, the clustered regularly interspaced short palindromic repeats (CRISPR)-associated 9 (Cas9) system offers several advantages: it is more user-friendly, more economical, faster and has a higher editing efficiency. 96 CRISPR/Cas9 has significantly broadened the application of stem cells in human regenerative medicine in general. Although there is no clear evidence that CRISPR/Cas9 is being used in cardiac regeneration, the potential of this genome-editing tool can be inferred for both in vitro and in vivo therapeutic applications, as well as for increasing our fundamental knowledge on the pathophysiology of the reparative mechanisms. Although tremendously promising, important questions remain about the safety and efficacy of potential gene-editing therapies (Table 2 ).
In Vivo Cell Reprogramming: Broadening the Boundaries of Regeneration
In 2006, the field of stem cell biology was revolutionized when mouse embryonic fibroblasts were partially reprogrammed into iPSCs by the overexpression of 4 mouse transcription Figure 2 . Regenerative therapies. Classification of different type of therapies in cell-based, cell-free or tissue engineering is done mostly from an academic perspective. In reality many of them converge and the combined use of different strategies may lead to better results. CPC indicates cardiac progenitor cell; CRISPR-Cas9, clustered regularly interspaced short palindromic repeats-associated 9; ECS, embryonic stem cell; and iPSC, induced pluripotent stem cell.
Table 2. Main Challenges and Recommendations for Future Preclinical Studies of Cardiac Regenerative Therapies
Type
Questions and Recommendations
General issues about preclinical studies
Animal models: use of comorbid or aged small and large animals might help to increase the translatability of the results. Male and female animals should be similarly represented. The pathophysiology of the underlying cardiac disease and associated comorbidities should be taken into account to decide on the treatment strategy and to interpret the therapeutic effects.
Study design: the rigor guidelines of Circulation Research 8 should be followed in all in vivo studies; in particular, keeping investigators blinded is critical, even in small animal studies. Delivery method should be carefully adjusted to the therapeutic modality and clinical context for maximal efficacy and safety.
Negative results should be reported, as their scientific value is equal to that of positive results.
To promote appropriate translation, it is critical to develop networks of experienced labs that work together to test the safety and efficacy of cell therapy in large animal models with a level of rigor comparable to multicenter clinical trials (CAESAR model), so as to avoid unnecessary or premature clinical studies. 9 Somatic stem/progenitor cells: Cardiac: CDCs, c-kit+, and CMC Noncardiac: BMMNCs, BMMSCs, AT-MSCs, CD34+cells, and UC-MSCs An effort should be made to identify the most effective cell type(s) or cell combinations for cardiac regeneration. Head-to-head comparisons of different cells should be made, preferably comparing dose-response relationships rather than arbitrary doses. It is possible that one specific cell type exhibits superior efficacy or alternatively, combinations of different cell types may be more efficacious in inducing regeneration.
The dose-response relationship should be elucidated for various cell types.
The possible cumulative effects of repeated doses should be assessed for each cell type along with the optimal number, timing, and frequency of repeated doses.
The optimal route of administration (intracoronary, transendocardial, or intravenous) should be determined by direct comparisons of the same cell type given via different routes.
The mechanism by which cell therapy promotes regeneration/repair remains unclear, although there is general agreement that it involves paracrine mechanisms rather than engraftment and differentiation. This is perhaps the single most important unresolved issue in the field.
The immunogenicity of allogeneic cells may be a limitation if repeated dosing is required; this issue should be elucidated.
iPSC-derived CMs
The main challenges related to iPSC-derived cardiomyocytes are as follows:
Heterogeneity: generated cells are frequently a mixture of atrial, ventricular, and conductive cells. Directing the differentiation toward ventricular-type cells may ensure better functional efficacy after transplantation.
Immaturity: generated cardiomyocytes exhibit structural and functional features of neonatal cells with poor integration into the host myocardium and lower long-term stability. To what extent the cells should be matured in vitro before transplantation is still unclear.
Ensuring adequate survival, engraftment, and coupling of transplanted cardiomyocytes with host cells is a priority.
Teratoma formation risk is inherent in the pluripotency of parental cells. Adequate purification of generated cardiomyocytes should be performed before transplantation to prevent oncogenicity.
The evidence that donor age may be associated with increased risk of significant abnormalities in iPSCs should be evaluated.
Gene therapy Efforts should be made to develop an ideal vector, that guarantees adequate gene transfer efficiency with long-term and regulated gene expression. Selection of the optimal delivery method is also important.
Use of nonintegrative gene transfer approaches (ie, plasmid vectors, mod-RNAs, and miRNAs) may reduce the potential risk of tumorigenicity.
With regard to genome editing tools (CRISPR/Cas9, ZFNs, and TALENs), several technical aspects should be improved: targetsite availability, editing efficiency, and off-target mutagenesis.
Extracellular vesicles Exosomes Microvesicles Vesicle contents
Because of the heterogeneity of vesicles, standardized methods to characterize their structure and their protein, nucleic acid, and lipid content are required. Definition of distinctive vesicular characteristics for different parental cell types would be desirable.
Isolation and purification methods should be standardized.
Based on their apparently short half-lives following systemic administration, efficient modes of delivery to diseased tissues should be accurately defined.
Possible organotropisms of vesicles based on their membrane composition should be carefully evaluated.
Careful comparisons of vesicles with parental cells should be done in rigorous in vivo studies.
More complex vesicle contents (eg, mitochondria or mtDNA) should begin to be evaluated as next-generation options.
(Continued )
factors, OSKM (Oct4, Sox2, Klf4, and c-Myc), using retroviral vectors. Moreover, this discovery disrupted the classical concept of the unidirectionality of the embryonic development first and aging later, opening a new field of research in regenerative and antiaging therapies. Although in the cardiovascular field reprogramming is mostly used to generate cardiomyocytes, there is no reason to think that this technology should be limited to these cells. By conventional reprogramming methods, cardiomyocytes can be obtained in vitro from terminally differentiated noncardiac somatic cells (usually fibroblasts), first converted into iPSCs. Many groups are studying the challenges associated with iP-SC-differentiated cardiomyocytes such as immaturity and heterogeneity with a consequent risk of arrhythmogenicity once transplanted into the heart 97 ( Table 2 ). The recognition that mature somatic cells can be transdifferentiated into cardiomyocytes, without passing through an intermediate pluripotent state 98 -a phenomenon also referred to as direct conversion or direct reprogramming-has several therapeutic implications. First, by bypassing the pluripotent state, the risk of tumorigenesis may be reduced; second, using patient's own cells avoids further immunologic issues (similar to iPSCs); and finally, the ability to directly convert noncardiomyocytes into cardiomyocytes in vitro offers the enticing possibility to do the same in vivo. Reprogramming by transdifferentiation spontaneously occurs in endogenous regeneration: after injury, transdifferentiation of atrial into ventricular cardiomyocytes or of cardiac fibroblast into endothelial-like cells have been described. 89 Exogenously induced transdifferentiation has been reported in studies that have delivered cardiac developmental transcription factors-GATA4 (cardiac developmental transcription factor), MEF2C (myocyte-specific enhancer factor 2C), and TBX5 (T-box protein 5)-directly into mouse hearts. 99 Interestingly, although the reprogramming efficiency of resident fibroblasts into cardiomyocytes achieved in vivo (10%-15%) was similar to that observed by the same group during in vitro conversion experiments, in vivo-generated cardiomyocytes were more fully reprogrammed and more mature. 99, 100 This suggests that the natural heart environment, absent in a culture dish, may enhance the cell fate switch.
Similarly, successful transdifferentiation of cardiomyocytes into conduction system cells has been reported in vitro and in vivo by ectopic activation of Tbx18 101 or the Notch signaling cascade. 102 If confirmed in humans, these strategies may revolutionize the treatment of cardiac conduction system disorders.
Finally, in a recent study, partial in vivo reprogramming by cyclic expression of OSKM ameliorated the age-related decline of tissue and organ regenerative capacity, with partial restoration of adult stem cells populations. 83 Although that study did not focus on the heart, the lifespan of reprogrammed progeric mice, which otherwise usually die from cardiovascular causes, was prolonged. This study highlights, once more, the connection between proregenerative and antiaging pathways and establishes reprogramming as a possible therapeutic strategy to target them both.
Proof-of-concept for in vivo reprogramming has been provided in animal models. However, substantial challenges remain ( Table 2 ) that should be addressed before any conclusion concerning the clinical utility of in vivo reprogramming therapies can be made.
Extracellular Vesicles and Vesicular Cargo as Future Cell-Free Therapeutics
Many investigators have transplanted somatic stem/progenitor cells into the heart with the hope that these cells would engraft, differentiate, and proliferate to form new myocardium. However, we have learned that most of the favorable effects of these cells are driven by paracrine factors. Therefore, cell-free therapies originated with the idea that delivering these factors alone may be sufficient to activate/potentiate endogenous regeneration by inducing (1) proliferation of preexisting cardiomyocytes; (2) in vivo reprogramming with generation of a reparative pool of cells (cardiomyocytes, conduction system cells, endothelial cells, etc); and (3) differentiation of resident progenitor cells.
Exosomes, the smallest of the secreted EVs, are nanoparticles (30-130 nm) that transport thousands of signaling molecules (RNAs, proteins, and lipids). Their potential as biomarkers of disease and as therapeutics is rapidly emerging. 103, 104 Native exosomes secreted by stem/progenitor cells or manipulated exosomes secreted by engineered stem cells or via treatment of isolated vesicles have been tested therapeutically. 105 Exogenously administered exosomes can have short-and long-distance effects by targeting specific cells and inducing molecular modifications in them. They have also been shown to activate immune responses and initiate In vitro large-scale generation of cardiomyocytes from iPSCs is one of the limiting factors. Related priority questions are outlined above in the corresponding section.
Adequate in vitro vascularization and perfusion of engineered constructs is necessary for generation of sufficiently large (several millimeters) tissue construct to replace a scar.
Generation of well-characterized banks of allogeneic hiPSC lines that offer human leukocyte antigen-matched products for most patients might help to alleviate immunologic problems.
Appropriate models to test safety and efficacy of human heart engineered tissue should be selected and developed.
AT-MSCs indicates adipose tissue-derived mesenchymal stem cells; BM-MSCs, bone marrow-derived mesenchymal stem cells; BMMNCs, bone marrow mononuclear cells; CAESAR, Consortium for Preclinical Assessment of Cardioprotective Therapies; CDCs, cardiosphere-derived cells; CM, cardiomyocytes; CMCs, cardiac mesenchymal cells; ESCs, embryonic stem cells; iPSCs, induced pluripotent stem cells; and UC-MScs, umbilical cord MSCs. Several preclinical studies suggest that the parental cells' effects can be recapitulated by secreted EVs. Exosomes secreted by mesenchymal stem cells suppressed vascular remodeling and inflammation in a murine model of pulmonary hypertension, 108 modulated angiogenesis, and protected cardiomyocytes from ischemic injury. 109 They also exerted proregenerative actions in cutaneous and skeletal muscle healing. Cardiosphere-derived cell-secreted exosomes induced cardiomyocyte proliferation and angiogenesis, increased the viable mass, decreased the scar, and preserved cardiac function in acute and chronic myocardial ischemia models. 110 There is also evidence that they exert an antisenescence effect by partly activating the telomere-telomerase axis. 85 EVs secreted by iPSCderived cardiovascular progenitors outperformed both their parent cells and iPSC-cardiomyocytes when injected in periinfarct myocardial regions in mice by significantly improving cardiac function and stimulating tissue reparative pathways. 111 Many, if not most, of the effects of exosomes are seemingly mediated by their RNA content, specifically microRNAs (miRs) and other noncoding RNAs. MiRs are small noncoding RNAs belonging to a class of silencing RNAs fundamental in posttranscriptional gene regulation. Their role in cardiac regeneration has been reviewed. 112 Different miRs can be used to induce direct conversion of fibroblasts to cardiomyocytes (in vivo reprogramming), to promote cardiomyocyte proliferation, and to drive the differentiation of iPSCs, or cardiac resident progenitors to cardiomyocytes. Importantly, a single miR can influence multiple pathways at once, thus orchestrating and coordinating the whole regenerative process.
Recently, the regenerative properties of some stem cells have been linked to mitochondrial transfer via EVs. 113 Moreover, these vesicles can transport the full mitochondrial genome (mtDNA) and transfer it to dysfunctional cells, restoring their activity. 114 Because mitochondrial dysfunction and cumulative mtDNA damage are related to cardiac aging and heart failure, 115, 116 and because the importance of mitochondria in mediating stem cell activity is becoming increasingly evident, 117 mitochondria-based therapies may be an attractive option to boost cardiac regeneration in the future. Cardiac transplantation of skeletal muscle-derived mitochondria to ameliorate ischemia/reperfusion injury is being explored in a phase II clinical trial (URL: http://www.clinicaltrials.gov. Unique identifier: NCT02851758).
Clinical use of EVs, however, is hindered by formidable logistic and cost-effectiveness issues related to the cost of producing large quantities of EVs for therapeutic administration. Key challenges related to the clinical use of EVs and miRs are summarized in Table 2 .
Cardiac Tissue Engineering
Why We Should Not Give Up on Bioartificial Heart? The exciting progress from the past decade in tissue engineering and stem cell biology has opened new and promising horizons for the development of 3-dimensional engineered heart constructs. Development of a perfect engineered heart construct or even an entire bioartificial heart is a potentially reachable goal but doing so requires overcoming a variety of biological and technical challenges. The aim of tissue engineering has traditionally been to provide living, forceproducing heart muscle tissue that can be transplanted on an injured heart and restore its normal function. Compared with cell therapy alone, the potential advantages of combining cells with scaffolds or hydrogels are (1) a higher retention of cells, which can improve their efficacy and safety; (2) selection of cells is performed in vitro, reducing the side effect of massive cell death in situ; and (3) tissues can be better quality controlled before implantation. It should be noted that all these benefits of engineered heart constructs are theoretical, as head-to-head comparative studies with cell therapies have not been performed. 118 Building an engineered tissue requires mimicking native ECM composition and structure to modulate implanted cell behavior. In an engineered tissue, the collagen fiber orientation mediates cell organization and alignment. This cell alignment, in turn, governs contractile forces generated by cardiac cells. 119, 120 Similarly, ECM components retain and provide necessary cues for cell differentiation, 121 which is key for differentiating stem cells towards specific cardiac lineages.
Another interesting concept is the intrinsic bioactivity of the components of the scaffolds/hydrogels. In general, acellular injectable biomaterials have been demonstrated to prevent adverse remodeling after myocardial infarction and some of them to promote angiogenesis in preclinical models. 122 However, randomized trials with the natural biomaterial alginate have failed to prove functional benefits. 123 In the future, codelivery of biomaterials with additional cell-free bioactive compounds (EVs, miRs, growth factors, etc) may be of especial interest. Prolonged release and desired localization of the delivery are some of the advantages that biomaterials can offer to the cell-free therapeutics, increasing their efficacy. Recently, hyaluronic acid hydrogel enriched with miR-302 injections in the mouse heart after myocardial infarction has been shown to increase cardiomyocytes proliferation and improve heart function. 124 Research in this field is just beginning.
Building a bioartificial heart remains a laudable and achievable end-goal of cardiovascular bioengineering. 125 With the creation of decellularized, biocompatible whole-heart scaffolds, many of the obstacles to engineering a complex vascularized cardiac tissue seem to have been obviated. The current challenge is to improve the processes required for recellularization-including those for cells, bioreactors, and physiological conditioning. Generation of sufficient numbers of cardiac cells, repopulation of the scaffold, and the maturation of a functional recellularized human-sized heart are some of the hurdles to be overcome. Maintaining sterility and quantifying readiness of the nascent organs are also critical for success. 126 At present, the largest recellularized heart has been the decellularized porcine heart reseeded with neonatal murine cardiac cells and human umbilical cord endothelial cells under simulated physiological conditions. The coronary arteries were reendothelialized, and measurable intrinsic myocardial electrical activity was observed in the newly generated organs after 10 days. 127 These promising results suggest that we may be able to build a bioartificial heart that can be transplanted in the near future if we overcome the issue of cost-the largest barrier to success in the field.
Conclusions
Despite the complexity of the biological processes that underlie regeneration and the suboptimal results obtained in many clinical studies to date, we have gained enormous knowledge in this field in recent years. We need to proceed with caution, responsibility, and scientific rigor. From a fundamental perspective, the classical concept of regeneration whereby a scar is replaced by large numbers of cardiomyocytes (as many as a billion), which were lost after a myocardial infarction, may not be plausible. Instead, we should consider regeneration as a global and balanced process, by involving the entirety of cardiac structures and cells types and by incorporating cellular rejuvenation as a new biological target. By replacing the classical concept with this new paradigm, we will approach the goal with a more realistic and achievable first step. Tables 1 and 2 summarize current challenges and priority areas for future studies, which we believe should be addressed to move the field forward. Future research in regenerative medicine should focus on these questions; this will help attain the ultimate goal of building a functional heart. 
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